Is Radiology's Commodity Myth About to Break?

Amy Cosler, Chief Growth & Partnerships Officer at Covera Health, tells CB Insights how they view the market, customer needs, and their company. Most people think about radiology the way they think about a blood test. You can go anywhere and get the same answer. Imaging has been treated as a commodity when it behaves nothing like one.

What Happened

In an executive interview published by CB Insights, Covera Health's Chief Growth and Partnerships Officer Amy Cosler challenged the prevailing view of radiology as a commodity service. Cosler argued that imaging quality varies significantly across providers, positioning Covera Health's quality-focused model against a market that has long treated scans as interchangeable. The interview covered market definition, client needs, and company positioning.

Why This Matters for B2B Marketers in Health Tech and Adjacent Verticals

Category reframing is one of the most underused moves in B2B marketing, and Covera Health is running the playbook in public. When a buyer assumes every option delivers the same outcome, price becomes the only lever and challengers lose. When you prove variance exists and quantify the cost of that variance, you reset the conversation around outcomes, risk, and total cost. For your team, the takeaway is not about radiology. It is about auditing where your buyers accept sameness that does not exist, then building the evidence to break the assumption.

The Starr Conspiracy's Take

Covera Health is doing what every challenger brand should be doing: attacking a lazy buyer assumption before attacking a competitor. The commodity frame is the enemy, not the incumbent. We see the same pattern in HR tech, where payroll, LMS, and ATS categories all get flattened into feature checklists that hide real outcome variance. If your differentiation story starts with capabilities, you have already lost. Start with the hidden cost of sameness, then prove your variance matters. Our take on category design as a demand generation strategy walks through how to build that evidence stack for skeptical buying committees.

What to Watch Next

Watch whether Covera Health's payer and employer partners begin publishing outcome variance data alongside cost data in 2026. If they do, expect other clinical categories, from pathology to physical therapy, to face similar decommoditization pressure. Health tech marketers should likely prepare quality-variance narratives now.

Related Questions

How do you decommoditize a category buyers see as interchangeable?

Start by quantifying outcome variance across providers and translating it into buyer-relevant risk. Publish the data, name the cost of sameness, and give buyers a new evaluation framework. Our guide to reframing commodity categories details the sequence.

Why does the commodity frame hurt challenger brands most?

When buyers assume all options are equal, they default to price, brand familiarity, or procurement inertia. Challengers lose all three defaults. Breaking the sameness assumption is the only path to a fair evaluation.

What signals suggest a category is ripe for reframing?

Look for wide outcome variance hidden by uniform pricing, buyer complaints about results that procurement ignores, and analyst reports that treat partners as feature-equivalent. Those three conditions almost always precede a category shakeup.